NCT04049266Phase 2, phase 3Terminated

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Study sponsor: Kodiak Sciences Inc · KOD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-11-17Actual
Enrollment · participants559Actual
Source updated2024-07-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview